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INTERVENTIONS
• Formulated a transdisciplinary team of multiple stakeholders, including 
clinical informatics and bedside providers to develop a “SmartPhrase” to 
promote rapid access to critical information.
• Developed pre-administration safety checks which included “hard stops” in 
the EHR “SmartPhrase” template.
• Formalized education: emails, posters, huddle presentations, and face-to-
face classes with return demonstration and validation of comprehension and 
usage.
• Conducted baseline, three-month, and six-month audits to evaluate for 
“SmartPhrase” usage and completion of documentation.
• Solicitated feedback and reported through the transdisciplinary team to 
identify opportunities for improvement and barriers to use, leading to 
template revisions.
• Re-educated users based on template modifications.
• Incorporated accurate completion of the “SmartPhrase” template via skills 
validation during new hire orientation.
CONCLUSIONS/DISCUSSION
• Nurses need to be actively involved in identifying barriers to care delivery to 
improve patient safety by initiating quality improvement projects.
• A defined location for the “SmartPhrase” made for easy access between 
shifts and future encounters to enhance patient centered care based on 
clinical status at time of treatment as well as ongoing treatment tolerance.
• The “SmartPhrase” allowed consistent documentation and dual-verification 
of pre-administration safeguards. 
• Chart audits helped identify barriers to documentation and delays in care, 
providing the opportunity for continued improvement.
• Implementing tools within the EHR based on standards of care and guidelines 
decreases organizational liability concerns while promoting safety.
• Regardless of routes or combination of treatments, the “SmartPhrase” offers 
a universal means of documentation in healthcare settings that utilize Epic® 
systems (Bakshi & Trivedi, 2018).
• Many organizations and healthcare systems utilize Epic® EHR systems which 
offer “SmartPhrases” that can be shared within an individual facility and/or 
network of healthcare delivery systems (LeFebvre & Smith, 2019).
• Ensures pre-administration safety checks are completed. 
• Completing the “SmartPhase” in advance supports stewardship of resources 
including nursing expertise/time, delays in treatment (bed/chair availability, 
admission/appointment time), and medication/supply cost.
• Promotes continuity of patient centered care by having a centralized location 
in the EHR for ease of retrieval across oncology patient’s ongoing and follow 
up treatment.
FURTHER RESEARCH/IMPLICATIONS FOR PRACTICE
GRAPHICAL DATABACKGROUND
• Chemotherapy-immunotherapies are high risk medications that can include 
multi-drug and multi-day regimens with narrow therapeutic indexes and high 
risk for toxicities.
• Susceptibility for errors exists if adherence to protocol is inconsistent or if 
pertinent patient specific information is omitted (LeFebvre & Smith, 2019).
• Prior to the creation of the “SmartPhrase” in the Electronic Health Record 
(EHR) pre-administration safety checks were on paper, not included in the 
EHR, not standardized among clinicians, and not completed every time.
• Chart audits revealed a need for consistent, centralized documentation to 
enhance patient safety while minimizing professional liability.
• A transdisciplinary team created a “SmartPhrase” template for streamlining 
relevant patient specific information and individualizing plans of care.
PURPOSE
• Create a documentation template which includes the nine components 
recommended by ONS guidelines for completed chemotherapy-
immunotherapy pre-administration checks (Neuss, et al., 2017).
• Improve patient-centered care and transitions in care.
GOALS
• Standardization of chemotherapy-immunotherapy pre-administration 
documentation to promote safety.
• Foster safe and seamless patient centered care throughout inpatient and 
outpatient settings and service lines.
• Ensure ONS recommendations for pre-administration checks includes a 
documented dual verification process.
• 95% or greater compliance in use of the “SmartPhrase”.
RESULTS AND OUTCOMES
• Practitioner utilization of the “SmartPhrase” exceeded the project goal of 
95% after implementation.
• Change from baseline use of “SmartPhase” documentation in the specific key 
areas: dual verification (↑100%), diagnosis and protocol (↑69%), drugs 
(maintained 100% utilization), consent (↑54%), education (↑37%), blood 
return (↑29%), dosages (↓6%), initial labs (↓6%), schedule (↑3%).
• Improved documentation and facilitated communication between providers 
within inpatient and outpatient settings and service lines.
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CHEMOTHERAPY / IMMUNOTHERAPY ADMINISTRATION NOTE 
 
Day: V for Verification note or Day # of Total Days 
 
Cancer Diagnosis: Free Text 
 
Hospital Admission Diagnosis: Free Text 
 
CHEMOTHERAPY/IMMUNOTHERAPY  
Protocol Deviation: No / Yes with Explanation 
Treatment Plan & Dosages Verified by RN and Pharmacist: Yes / No 
 





Free Text mg 
mcg 
units 








Initial Verification/RN Check 
Rate Adjusted See MAR 
Completed 
Free Text 
*Lines can be added for multiple drug regimens 
 




Consent Signed: Yes / No 
 
Body surface area is *AUTO POPULATES* meters squared. 
 
Review of Labs: Yes / No 
Urine PH within administration parameters (if applicable): Yes / No / NA 
 
Lab Results 
Component Value Date 
 *AUTO POPULATES*   
 
Education: Patient received drug information from Micromedex and verbalizes understanding of side effects and 
toxicities: Yes / No 
Patient was advised to report symptoms or pain/discomfort at infusion site: Yes / No 
 
Plan of Care Initiated/Updated: Yes / No 
 
Condition of IV Site Pre-Treatment:   
Line Type Blood 
Return 
Assessment/Condition Comments (Awaiting Tip 
Confirmation, tPA, etc.) 
Pt has a port, tunneled line, PICC, 
non-tunneled line / short term 
catheter, peripheral line, 
peripheral inserted midline, other 
Yes / No dressing dry and intact 
no erythema 




*Definition of actions available upon request 
 IM—intramuscular; IT—intrathecal; MAR—medication administration record; NA—not applicable; PICC—peripherally inserted central catheter;
Pt—patient; SQ—subcutaneous; tPA—tissue plasma activator 
Note. Image courtesy of Providence Regional Medical Center Everett. Used with permission PRMCE
